Trial reportJournal of neurology2026
Comprehensive effects of Parkinson's disease multimodal complex treatment (PD-MCT): a two-center prospective trial.
Trial report in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hospital-to-Home Neurological Transition Care: A Scoping Review Across Selected Chronic Neurological Disorders.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that impair quality of life. Inpatient Parkinson's disease Multimodal Complex Treatment (PD-MCT) integrates individualized medication adjustments with intensive multiprofessional therapies and improves symptoms and functional abilities. However, evidence remains limited regarding which symptom domains benefit most and which patient characteristics predict treatment response, particularly in advanced PD and with respect to cognitive status.
methodsThis two-center, prospective cohort study included 53 adults with advanced idiopathic PD who underwent 14-21 days of inpatient PD-MCT at two centers. Inclusion criteria comprised a diagnosis of PD according to German and International Parkinson and Movement Disorder Society guidelines and the ability to walk at least 50 m with assistive devices. Patients with atypical parkinsonian syndromes or comorbidities severely affecting gait were excluded. Motor function, non-motor symptoms, cognition, and quality of life were assessed at baseline and before discharge. A 3-month follow-up evaluated symptom burden and continuation of supportive therapies. Primary outcomes were changes in motor symptom severity (ΔMDS-UPDRS-III), overall motor function (ΔMDS-UPDRS-II + III + IV), and quality of life (ΔPDQ-39).
resultsPD-MCT significantly improved motor symptom severity (-5.2 ± 10.6), overall motor function (-10.6 ± 10.7), and quality of life (-9.3 ± 16.2). Additional benefits were observed in non-motor symptoms, cognition, mood, and functional measures. Greater baseline motor impairment and poorer quality of life predicted larger short-term improvements, while baseline cognition did not influence treatment effectiveness. Predictive modelling showed modest predictive value of baseline motor scores for changes in MDS-UPDRS-III.
conclusionThese findings confirm that PD-MCT provides clinically meaningful motor, non-motor, cognitive, and quality-of-life benefits in advanced PD, with strongest effects in patients with high baseline symptom burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.